Phelan—McDermid syndrome associated with a novel heterozygous mutation in the SHANK3 gene

Close metadata

Recommended articles:

Impact of COVID-19 on some neurological and psychological features in epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):7-11

Epileptic syndromes associated with focal clonic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):41-45

Possibilities of optimizing therapy in COVID-19 survivors with focal epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):130-136

The impact of antiepileptic therapy on sleep disorders in women with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(5-2):105-109

Psychogenic non-epileptic seizures in autistic spectrum disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(7):112-117

A case of a pathological variant of the PRRT2 gene in twins with paroxysmal kinesiogenic dyskinesia. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(9-2):83-86

Bacosides: a study of neurobiological activity, prospects for application. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(10):54-59

MR morphometry in epileptology: progress and perspectives. Burdenko's Journal of Neurosurgery. 2023;(3):113-119

Surgical treatment of focal drug-resistant epilepsy associated with temporal lobe encephalocele. Burdenko's Journal of Neurosurgery. 2024;(1):39-47

Phelan-McDermid syndrome (PMS) is a hereditary disorder associated with microdeletions of chromosome 22q13 or point mutations in SHANK3, characterized by mental and speech delays, intellectual disability, epilepsy and autism spectrum disorder. We describe a case PMS associated with a heterozygous mutation c.2486delC (p.Pro829fs) in SHANK3. The diagnostic pathway of a female patient with PMS took more than 7 years; the reason for treatment was the onset of epileptic seizures and impaired speech development. The existence of different types of rearrangements and genomic variations can explain the high clinical variability observed in individuals with PMS. Only molecular diagnosis can accurately diagnose individuals with PMS for follow-up and medical genetic counselling of families.

Keywords:

Phelan-McDermid syndrome

SHANK3

autism spectrum disorder

epilepsy

intellectual disability

Authors:

D.V. I

Far Eastern State Medical University

Scopus AuthorID: 57226670660
ORCID: 0000-0002-9967-0279

T.N. Proskokova

Far-East State Medical University

ORCID: 0000-0002-5209-2440

Received:

10.03.2023

Accepted:

22.03.2023

List of references:

Heilstedt HA, Ballif BC, Howard LA, et al. Physical Map of 1p36, Placement of Breakpoints in Monosomy 1p36, and Clinical Characterization of the Syndrome. Am J Hum Genet. 2003;72(5):1200-1212. https://doi.org/10.1086/375179
Delahaye A, Toutain A, Aboura A, et al. Chromosome 22q13.3 Deletion Syndrome with a De Novo Interstitial 22q13.3 Cryptic Deletion Disrupting SHANK3. Eur J Med Genet. 2009;52(5):328-332. https://doi.org/10.1016/j.ejmg.2009.05.004
Dadali EL, Kanivets IV, Sharkova IV. Clinical and genetic characteristics of syndrome Phelan-McDermid. Medical Genetics. 2015;14(11):14-17. (In Russ.).
https://doi.org/10.17650/2073-8803-2016-11-4-33-44 https://doi.org/10.17650/2073-8803-2016-11-4-33-44
Nasyrov AA, Kalashnikova TP, Dovganiuk MV. Phelan-McDermid syndrome. Clinical observation. Mental Health of Children and Adolescent. 2019;19(1):83-88. (In Russ.).
Phelan K, McDermid HE. The 22q13.3 deletion syndrome (Phelan-McDermid syndrome). Mol Syndromol. 2012;2(3-5):186-201.
Soorya L, Kolevzon A., Zweifach J, et al. Prospective Investigation of Autism and Genotype-Phenotype Correlations in 22q13 Deletion Syndrome and SHANK3 Deficiency. Mol Autism. 2013;4(4):18. https://doi.org/10.1186/2040-2392-4-18
Sarasua SM, Boccuto L, Sharp JL, et al. Clinical and Genomic Evaluation of 201 Patients with Phelan-McDermid Syndrome. Hum Genet. 2014;133(7):847-859. https://doi.org/10.1007/s00439-014-1423-7
Philippe A, Boddaert N, Vaivre-Douret L, et al. Neurobehavioral profile and brain imaging study of the 22q13.3 deletion syndrome in childhood. Pediatrics. 2008;122(2):376-382. https://doi.org/10.1542/peds.2007-2584
Uchino S, Waga C. SHANK3 as an autism spectrum disorder-associated gene. Brain Dev. 2013;35(2):106-110. https://doi.org/10.1016/j.braindev.2012.05.013.
Leblond CS, Nava C, Polge A, et al. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet. 2014;10(9):e1004580. https://doi.org/10.1371/journal.pgen.1004580
Sarasua SM, Dwivedi A, Boccuto L, et al. 22q13.2q13.32 genomic regions associated with severity of speech delay, developmental delay, and physical features in Phelan-McDermid syndrome. Genet Med. 2014;16(4):318-328. https://doi.org/10.1038/gim.2013.144
Cusmano-Ozog K, Manning MA, Hoyme HE. 22q13.3 Deletion Syndrome: A Recognizable Malformation Syndrome Associated with Marked Speech and Language Delay. Am J Med Genet. 2007;145C:393-398. https://doi.org/10.1002/ajmg.c.30155
Dhar SU, del Gaudio D, German JR, et al. 22q13.3 Deletion Syndrome: Clinical and Molecular Analysis Using Array CGH. Am J Med Genet. 2010;152A:573-581. https://doi.org/10.1002/ajmg.a.33253
Sarasua SM, Dwivedi A, Boccuto L, et al. Association between Deletion Size and Important Phenotypes Expands the Genomic Region of Interest in Phelan-McDermid Syndrome (22q13 Deletion Syndrome). J Med Genet. 2011;48:761-766. https://doi.org/10.1136/jmedgenet-2011-100225
Tabet AC, Rolland, T, Ducloy M, et al. A Framework to Identify Contributing Genes in Patients with Phelan-McDermid Syndrome. NPJ Genom Med. 2017;2:32. https://doi.org/10.1038/s41525-017-0035-2
Samogy-Costa CI, Varella-Branco E, Monfardini F, et al. A Brazilian Cohort of Individuals with Phelan- McDermid Syndrome: Genotype-Phenotype Correlation and Identification of an Atypical Case. J Neurodevelop Disord. 2019;11(1):13. https://doi.org/10.1186/s11689-019-9273-1
Anderlid BM, Schoumans J, Annerén G, et al. FISH-mapping of a 100-kb terminal 22q13 deletion. Hum Genet. 2002;110(5):439-443. https://doi.org/10.1007/s00439-002-0713-7
Bonaglia MC, Giorda R, Borgatti R, et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet. 2001;69(2):261-268. https://doi.org/10.1086/321293
Phelan K, Rogers RC, Boccuto L. 22q13.3 Deletion Syndrome, Chromosome 22q13.3 Deletion Syndrome, Deletion 22q13 Syndrome. Genereviews. 2018.
De Rubeis S, Siper PM, Durkin A, et al. Delineation of the Genetic and Clinical Spectrum of Phelan-McDermid Syndrome Caused by SHANK3 point Mutations. Mol Autism. 2018;9:31. https://doi.org/10.1186/s13229-018-0205-9
Kolevzon A, Delaby E, Berry-Kravis E, et al. Neuropsychiatric Decompensation in Adolescents and Adults with Phelan- McDermid Syndrome: a Systematic Review of the Literature. Mol Autism. 2019;10:50. https://doi.org/10.1186/s13229-019-0291-3
Ryzhkova OP, Kardymon OL, Prohorchuk EB, et al. Guidelines for the interpretation of massive parallel sequencing variants (update 2018, v2). Medical Genetics. 2019;18(2):3-23. (In Russ.). https://doi.org/10.25557/2073-7998.2019.02.3-23
Nevado J, García-Miñaúr S, Palomares-Bralo M, et al. Variability in Phelan-McDermid Syndrome in a Cohort of 210 Individuals. Front Genet. 2022;13:652454. https://doi.org/10.3389/fgene.2022.652454
Bonaglia MC, Giorda R, Beri S, et al. Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome. PLoS Genet. 2011;7:e1002173.
Figura MG, Coppola A, Bottitta M, et al. Seizures and EEG pattern in the 22q13.3 deletion syndrome: clinical report of six Italian cases. Seizure. 2014;23:774-779.
Holder JL, Quach MM. The spectrum of epilepsy and electroencephalographic abnormalities due to SHANK3 loss of function mutations. Epilepsia. 2016;57:1651-1659.
Aldinger KA, Kogan J, Kimonis V, et al. Cerebellar and posterior fossa malformations in patients with autism-associated chromosome 22q13 terminal deletion. Am J Med Genet A. 2013;161A:131-136.
Oberman LM, Boccuto L, Cascio L, et al. Autism spectrum disorder in Phelan-McDermid syndrome: initial characterization and genotype-phenotype correlations. Orphanet J Rare Dis. 2015;10:105.
Reierson G, Bernstein J, Froehlich-Santino W, et al. Characterizing regression in Phelan McDermid Syndrome (22q13 deletion syndrome). J Psychiatr Res. 2017;91:139-144. https://doi.org/10.1016/j.jpsychires.2017.03.010.
Bozdagi O, Tavassoli T, Buxbaum JD. Insulin-like growth factor1 rescues syn- aptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism. 2013;4:9.
Shcheglovitov A, Shcheglovitova O, Yazawa M, et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature. 2013;503:267-271.
Kolevzon A, Bush L, Ting Wang A, et al. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism. 2014;5:54.

Close metadata